Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
about
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosisLapatinib for metastatic breast cancer overexpressing HER2Critical appraisal of trastuzumab in treatment of advanced stomach cancerCapecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancerA phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursSelectivity and therapeutic inhibition of kinases: to be or not to be?The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerPersonalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionCardiac toxicity of trastuzumab in elderly patients with breast cancerMolecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future DirectionsTrial watch - inhibiting PARP enzymes for anticancer therapyFirst-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersCurrent Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerTargeted therapies with companion diagnostics in the management of breast cancer: current perspectivesMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerChanging strategies for target therapy in gastric cancerLung cancer biomarkers, targeted therapies and clinical assaysHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsCompanion diagnostics for the targeted therapy of gastric cancerTargeting RTK Signaling Pathways in CancerInfluence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analysesEmerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancerHealth economic aspects of breast cancer treatment: the compulsory health insurances' viewTargeted therapy for HER2 positive breast cancerNewer therapies for the treatment of metastatic breast cancer: a clinical updateManagement of solitary and multiple brain metastases from breast cancerApplication of metabolomics in drug resistant breast cancer researchTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyPotential of afatinib in the treatment of patients with HER2-positive breast cancerNeoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implicationsAdvances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized MedicinePI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerProfiling and targeting HER2-positive breast cancer using trastuzumab emtansineQuantification of HER family receptors in breast cancerThe promise of circulating tumor cell analysis in cancer managementHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerInflammatory breast cancer: what we know and what we need to learnDual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugsIntermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.
P2860
Q21132316-FDC6E6A6-0626-4BD8-9E22-4440A3E486EBQ24203605-4FB18690-AAC3-4FA2-BAFD-C8F845F844A3Q24604411-FDE59170-59C3-4F77-ADCC-6447D49BD7B2Q24633167-1DB9FF0C-AA47-4DE9-BFFA-CF81066A5D12Q24653999-B2E0C6C3-97D8-4E48-BA8F-F5540E62500DQ24656006-E37E6445-2BE0-4019-99F2-5D57A55CB60CQ24656159-40145AB5-785C-4C6C-8649-4C7D11E36984Q26738860-B5B0956F-E1CA-45F9-A043-9E11C4A885A4Q26741182-398EDC41-45B8-428D-93AE-82FFC49ECFD8Q26741320-461CC616-7AC6-4E57-A3A3-7AECBA7E1076Q26745673-FCAA5386-C8C9-4786-8F69-F3E637E1158BQ26746081-F0C3A624-90B0-4A80-AB28-403B0E629B12Q26751473-3BCCB348-C757-45E3-9FBA-BA621552B429Q26764987-4DFE8173-E560-427F-AF7E-73D82F2430C7Q26768119-3BF07B97-5358-46CC-A8A2-AE06E330C0F9Q26772969-1A75B9B9-6A0C-447E-AC53-071AAFE25048Q26774513-F6F0D44A-63CA-4302-BC1A-95AFD1FFAF04Q26775396-2B5BC1FB-AF3C-4A99-B150-BAF034B2ADC6Q26777681-9C8B4E2B-64F8-4FEE-A06F-C140D2AB526BQ26780298-CFA7DF7C-38EA-41D0-ABA8-68B33AB30C25Q26781278-451F2424-4F1C-4658-B3F6-193BC41279E6Q26786243-5CEC30F1-AD5E-4FF8-B8CF-7339D309D1F2Q26824799-A514B433-FFA2-4572-8D55-E2E22FD8E1DDQ26826505-05440DC6-EC4F-4F82-97FD-6C1BF0EE7249Q26830496-06186AFD-C63B-4C27-8215-9EF718D4345BQ26865260-F148FA42-AD8A-40CD-BD05-6A9BB7478FFEQ26865562-3BDBA579-F5E1-4579-9B3B-B2D8A969405AQ26866291-1E3BB2D3-C91B-44F1-8D68-44E2D82A9A7DQ26993238-A2BBA1EA-C1B1-44E9-A42F-C33B65300429Q26999050-31AE387C-EB48-4CCD-BC98-6CB505FCE1E2Q27001729-75CCD617-8137-43F9-B4DB-6F34D61192ADQ27001994-4A8DAB6A-4E39-4EAA-91A2-4C98CAF809F1Q27006181-23D8AE0F-98C6-40B2-B423-7227ED32FB75Q27015048-6B6ADE0B-B052-49EB-92DC-EABD72426670Q27015506-B321C614-A45F-4C14-A46F-E3DFF29D20D5Q27022113-BE1497A1-7C52-4A2A-817A-3FA9A7B995FCQ27025863-5A7E327D-CD9D-4871-9378-B91B0897F458Q27028128-84D42918-EF55-4AFB-8893-CE89A93229DEQ27303674-F935B99C-7970-4462-A891-13BED3F70C43Q27315979-477DD7D0-046E-4B94-A967-0A4FE6A59123
P2860
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@ast
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@en
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@nl
type
label
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@ast
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@en
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@nl
prefLabel
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@ast
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@en
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@nl
P2093
P50
P3181
P356
P1476
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
@en
P2093
Bella Kaufman
C Gilles Romieu
Charles E Geyer
David Cameron
Deborah Lindquist
John Crown
John Forster
Mario Campone
Mark Berger
Neville Davidson
P304
P3181
P356
10.1056/NEJMOA064320
P407
P577
2006-12-28T00:00:00Z